The University of California (“UC”) and The Broad Institute, Inc. (“Broad”) are among the leaders in the development of CRISPR technology. Both UC and Broad filed patent applications for claims broadly drawn to CRISPR-Cas9 systems and methods of DNA editing. These parties are currently engaged in litigation over patents concerning the potentially most lucrative application of CRISPR technology – the use of CRISPR-Cas9 in plant and animal (eukaryotic) cells. The outcome of this litigation will affect control of the CRISPR platform and development of the technology.
The post The CRISPR Tug of War appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Clause 8: Ed Murgitroyd on Disrupting IP Services and Leading a Publicly Traded IP Law Firm
- USPTO Names New Advisory Board Members on Heels of PPAC Report Forecasting Downward Trend in Finances
- APPLE JAZZ Trademark Fight Continues at CAFC
- Straight to the Prompt: IP Lawyers Must Develop AI Skills NOW
- This Week in Washington IP: Evaluating the U.S.’s Role in IP Leadership, CHIPS Act Successes and Semiconductor Production, and the White House Policy on AI